Morgan Stanley Maintains Equal-Weight on ViewRay, Lowers Price Target to $4
Morgan Stanley maintains ViewRay (NASDAQ:VRAY) with a Equal-Weight and lowers the price target from $7 to $4.
Piper Sandler Maintains Overweight on ViewRay, Lowers Price Target to $7
Piper Sandler analyst Jason Bednar maintains ViewRay (NASDAQ:VRAY) with a Overweight and lowers the price target from $9 to $7.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
ViewRay’s MRI-Guided Stereotactic Body Radiotherapy Shows Favorable Toxicity Profile In Prostate Cancer
ViewRay Inc (NASDAQ: VRAY) has announced the
ViewRay: Q4 Earnings Insights
ViewRay (NASDAQ:VRAY) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
ViewRay reported in-line EPS of $-0.16 versus an estimate of $-0.16.